Literature DB >> 27405854

The Roles of the Charlson Comorbidity Index and Time to First Antibiotic Dose as Predictors of Outcome in Pneumococcal Community-Acquired Pneumonia.

Daniel Franzen1, Marisa Lim2, Daniel J Bratton2, Stefan P Kuster3, Malcolm Kohler2.   

Abstract

PURPOSE: In this retrospective study, we aimed to investigate the role of comorbidities using the Charlson comorbidity index (CCI) and time to first antibiotic dose (TFAD) in patients with pneumococcal community-acquired pneumonia (PCAP).
METHODS: All consecutive ER admissions with PCAP who were hospitalized in the University Hospital, Zurich between 2006 and 2012 were included. The primary outcome was to determine possible determinants of all-cause in-hospital mortality (ACIHM). The second endpoint was to detect risk factors for adverse events (AEs) and determinants of length of stay (LOS).
RESULTS: 108 subjects (mean age 57.6 years) were included. The median (IQR) CCI was 4 (1, 8). The median (IQR) TFAD was 210 (150, 280) min. ACIHM was 6.5 % (7/108), and median (IQR) LOS was 9 (6, 14) days. PCAP-related AEs were observed in 57 cases (52.8 %). In the multivariable analysis, neither CCI nor TFAD was associated with the outcome measures. Pneumonia severity index (PSI) was the only statistically significant predictor of ACIHM (HR 1.31/10 point increase, 95 % CI 1.12-1.53, p = 0.001) and AE rate (OR 1.31, 95 % CI 1.15-1.50, p < 0.001).
CONCLUSIONS: In this study including comparatively young patients with rather mild disease severity, we found no strong evidence supporting that CCI or TFAD influenced short-term outcome measures of PCAP. Yet, pneumonia severity appears to be the most important factor for the outcome.

Entities:  

Keywords:  Comorbidity; Pneumococcal community-acquired pneumonia; Pneumonia severity index; Short-term outcome; Time to first antibiotic dose

Mesh:

Substances:

Year:  2016        PMID: 27405854     DOI: 10.1007/s00408-016-9922-z

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  22 in total

Review 1.  Antibiotic Therapy for Adults Hospitalized With Community-Acquired Pneumonia: A Systematic Review.

Authors:  Jonathan S Lee; Daniel L Giesler; Walid F Gellad; Michael J Fine
Journal:  JAMA       Date:  2016-02-09       Impact factor: 56.272

2.  Initial management of and outcome in patients with pneumococcal bacteremia: a retrospective study at a Swiss university hospital, 2003-2009.

Authors:  A-M Giner; S P Kuster; R Zbinden; C Ruef; B Ledergerber; R Weber
Journal:  Infection       Date:  2011-11-08       Impact factor: 3.553

3.  Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults.

Authors:  Lionel A Mandell; Richard G Wunderink; Antonio Anzueto; John G Bartlett; G Douglas Campbell; Nathan C Dean; Scott F Dowell; Thomas M File; Daniel M Musher; Michael S Niederman; Antonio Torres; Cynthia G Whitney
Journal:  Clin Infect Dis       Date:  2007-03-01       Impact factor: 9.079

4.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

5.  Delayed administration of antibiotics and atypical presentation in community-acquired pneumonia.

Authors:  Grant W Waterer; Lori A Kessler; Richard G Wunderink
Journal:  Chest       Date:  2006-07       Impact factor: 9.410

6.  Determinants of outcome in patients with bacteraemic pneumococcal pneumonia: importance of early adequate treatment.

Authors:  José Garnacho-Montero; Emilio García-Cabrera; Ana Diaz-Martín; Jose A Lepe-Jiménez; Patricia Iraurgi-Arcarazo; Rocio Jiménez-Alvarez; Jaume Revuelto-Rey; Javier Aznar-Martín
Journal:  Scand J Infect Dis       Date:  2010-03

7.  Early administration of antibiotics does not shorten time to clinical stability in patients with moderate-to-severe community-acquired pneumonia.

Authors:  Steven H Silber; Christopher Garrett; Rakesh Singh; Angela Sweeney; Carl Rosenberg; Diana Parachiv; Tobi Okafo
Journal:  Chest       Date:  2003-11       Impact factor: 9.410

8.  Early administration of the first antimicrobials should be considered a marker of optimal care of patients with community-acquired pneumonia rather than a predictor of outcomes.

Authors:  Jose Bordon; Stefano Aliberti; Padmaraj Duvvuri; Timothy Wiemken; Paula Peyrani; Inez Natividad; Alfredo Caceres-Lara; Robert Delapenha; Francesco Blasi; Julio Ramirez
Journal:  Int J Infect Dis       Date:  2013-03-16       Impact factor: 3.623

9.  The presence of pneumococcal bacteremia does not influence clinical outcomes in patients with community-acquired pneumonia: results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort study.

Authors:  José Bordón; Paula Peyrani; Guy N Brock; Francesco Blasi; Jordi Rello; Thomas File; Julio Ramirez
Journal:  Chest       Date:  2008-01-15       Impact factor: 9.410

10.  Pneumonia severity, comorbidity and 1-year mortality in predominantly older adults with community-acquired pneumonia: a cohort study.

Authors:  Thomas Wesemann; Harald Nüllmann; Marc Andre Pflug; Hans Jürgen Heppner; Ludger Pientka; Ulrich Thiem
Journal:  BMC Infect Dis       Date:  2015-01-08       Impact factor: 3.090

View more
  2 in total

1.  Association between Charlson comorbidity index score and outcome in patients with stage IIIB-IV non-small cell lung cancer.

Authors:  Lei Zhao; Lai-Han Leung; Jing Wang; Huihui Li; Juanjuan Che; Lian Liu; Xiaojun Yao; Bangwei Cao
Journal:  BMC Pulm Med       Date:  2017-08-15       Impact factor: 3.317

2.  The effect of comorbidities for the prognosis of community-acquired pneumonia: an epidemiologic study using a hospital surveillance in Japan.

Authors:  Mai Thi Ngoc Nguyen; Nobuyuki Saito; Yukiko Wagatsuma
Journal:  BMC Res Notes       Date:  2019-12-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.